A Multicenter Randomized Double-Blind Placebo-Controlled Phase III Study to Evaluate the Efficacy and Safety of Elafibranor in Patients with Nonalcoholic Steatohepatitis (NASH) and fibrosis.

Brief description of study

The purpose of this study is to see if an investigational drug called Elafibranor is safe and helps people with NASH. NASH is a liver disease associated with inflammation and liver cell injury visible under a microscope with a liver biopsy. This condition may lead to advanced fibrosis and cirrhosis and deserves serious medical management. Once cirrhosis has developed, the serious complications of liver disease may occur, including liver failure. NASH might also lead to liver cancer. At this time, there are no drugs approved for the treatment of NASH.


Clinical Study Identifier: s17-00920
ClinicalTrials.gov Identifier: NCT02704403


If you are registered as a volunteer, please login to the dashboard to send referrals.